HI
FPRX

HBK Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

HBK Investments’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-53,407
Closed -$1.93M – 1060
2017
Q1 		$1.93M Buy
53,407
+45,389
+566% +$2M 0.02% 331
2016
Q4 		$402K Sell
8,018
-4,382
-35% -$230K ﹤0.01% 587
2016
Q3 		$651K Sell
12,400
-62,404
-83% -$2.98M 0.01% 599
2016
Q2 		$3.09M Buy
74,804
+7,653
+11% +$333K 0.02% 322
2016
Q1 		$2.73M Sell
67,151
-8,249
-11% -$284K 0.03% 375
2015
Q4 		$3.13M Buy
75,400
+56,900
+308% +$1.91M 0.03% 317
2015
Q3 		$285K Buy
+18,500
New +$398K ﹤0.01% 861

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

HBK Investments's FPRX Position: Q2 2017 in Review

HBK Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2017, closing a stake of 53,407 shares — an estimated $1.93M sold.

HBK Investments first reported a position in FPRX in Q3 2015 and held it in 7 quarters. The position peaked at $3.13M in Q4 2015. 123 funds tracked by Wall St. Rank hold FPRX as of Q2 2017.

  • HBK Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • HBK Investments sold 53,407 Five Prime Therapeutics, Inc. shares in Q2 2017, an estimated $1.93M.
  • HBK Investments first reported a position in Five Prime Therapeutics, Inc. in Q3 2015 and held it in 7 quarters.
  • HBK Investments's Five Prime Therapeutics, Inc. position peaked at $3.13M in Q4 2015.
  • 123 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2017.

Based on HBK Investments's 13F filing for Q2 2017, filed 14 Aug 2017.